当前位置： SCI文献检索 > Multiple Sclerosis and Related Disorders期刊下所有文献 > End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?

End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?

Abstract：

BACKGROUND:Many natalizumab treated patients experience end of dose interval (EDI) symptoms towards the end of the administration cycle. Natalizumab has previously shown to influence cytokine profiles in relapsing remitting MS patients. We hypothesize that EDI symptoms might be explained by variability in serum cytokine levels during natalizumab treatment. METHODS:42 relapsing remitting MS patients were included. Participants were evaluated before natalizumab administration (day 0) and 7 days afterwards (day 7). At both time points fatigue, depressed mood and cognition were evaluated using the fatigue severity scale (FSS), the visual analogue scale for fatigue (VAS-F), the symbol digit modality test (SDMT) and the inventory for depressive symptomatology (IDS-SR). Serum samples were tested for concentrations of IL-6, IFN-γ and TNF-α at both timepoints. On day 7 an additional EDI questionnaire was completed. Data were analyzed with SPSS by means of non-parametric tests. RESULTS:EDI symptoms were reported by 59.5%. Although fatigue was most frequently reported, fatigue scales did not significantly change from day 0 to 7 in (fatigued) EDI patients. Mood and cognition significantly ameliorated in both EDI and non-EDI patients. Cytokines remained stable at day 0 vs 7 except for a significant increase in IFN-γ. On day 0, IFN-γ concentration was positively correlated with a depressed mood in the whole cohort, and with mood and fatigue in the EDI group. Depressed mood positively whilst cognition negatively correlated with IFN-γ concentration on day 0 in the EDI subgroup reporting fatigue. No significant correlations between IL-6 nor TNF-α and symptom scores could be found. CONCLUSION:In our study EDI symptoms could not be objectified since EDI and non-EDI groups did not differ in terms of change in mood, cognition and fatigue between day 0 and 7 suggesting that symptom recrudescence could be a subjective experience. Although our results need to be interpreted cautiously, we found no clear correlation between studied serum cytokines concentrations and the occurrence of EDI symptoms.

journal_name

Mult Scler Relat Disord

journal_title

Multiple sclerosis and related disorders

authors

Cathérine D,Annelien P,Anne S,Luc A,Liesbeth VH,Gerlo S,Guy L

doi

10.1016/j.msard.2020.102020

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

102020

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(20)30096-1

journal_volume

41

pub_type

杂志文章

相关文献

Multiple Sclerosis and Related Disorders文献大全
  • Hypocomplementemic urticarial vasculitis and multiple Sclerosis: A rare association or an atypical presentation?

    abstract：BACKGROUND:Multiple Sclerosis (MS) has been associated with several immune-mediated diseases but the mechanisms that explain such associations, as well as their implications in clinical practice and treatment are rarely discussed. CASE PRESENTATION:We report the case of a patient with a history of MS since she was 27 ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.02.020

    authors： Durães J,Gonçalo M,Sousa L,Macário MC

    更新日期：2019-05-01 00:00:00

  • Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis.

    abstract：BACKGROUND:Peak width of skeletonized mean diffusivity (PSMD) is a novel and fully automated, MRI biomarker, which has shown clinical relevance in cerebral small vessel diseases (SVD). We aimed here to assess PSMD levels across the brain of patients with multiple sclerosis (MS), in comparison to normal controls (NC) an...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2018.11.011

    authors： Vinciguerra C,Giorgio A,Zhang J,Di Donato I,Stromillo ML,Tappa Brocci R,Federico A,Dotti MT,De Stefano N

    更新日期：2019-01-01 00:00:00

  • New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases.

    abstract：:Acquired demyelinating CNS syndromes include a broad spectrum of clinical phenotypes and different entities can overlap. Therefore, differential diagnosis is still challenging. A humoral immune reaction against myelin oligodendrocyte glycoprotein (MOG) is present in a subgroup of these patients, particularly in childr...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2018.02.023

    authors： Di Pauli F,Reindl M,Berger T

    更新日期：2018-05-01 00:00:00

  • Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review.

    abstract：BACKGROUND:Research on Virtual Reality (VR) based motor rehabilitation for people with multiple sclerosis (MS) is rapidly growing in popularity, although few studies have focused on the upper limb (UL). The aims of this review were to investigate the effect of VR interventions on UL function in people with MS and deter...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2020.102610

    authors： Webster A,Poyade M,Rooney S,Paul L

    更新日期：2020-10-31 00:00:00

  • The relation between memory and decision-making in multiple sclerosis patients.

    abstract：BACKGROUND:Impairments in long-term and working memory are widespread in Multiple Sclerosis (MS), setting on in early disease stages. These memory impairments may limit patients' ability to take informed and competent medical decisions, too. In healthy populations, memory abilities predict decision quality across a wid...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.101433

    authors： Hoffmann JA,Bareuther L,Schmidt R,Dettmers C

    更新日期：2020-01-01 00:00:00

  • Antecedent anti-NMDA receptor encephalitis in two patients with multiple sclerosis.

    abstract：:Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder characterised by psychiatric symptoms, movement disorder and seizures often evolving into a severe encephalopathy. An overlap has recently been recognised between anti-NMDAR encephalitis and inflammatory demyelinating disorders, particul...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2016.12.009

    authors： Baheerathan A,Brownlee WJ,Chard DT,Shields K,Gregory R,Trip SA

    更新日期：2017-02-01 00:00:00

  • Multiple intracranial lesions with lung adenocarcinoma: A rare case of MOG-IgG-associated encephalomyelitis.

    abstract：BACKGROUND:Myelin oligodendrocyte glycoprotein (MOG) is an important marker on the surface of oligodendrocytes and is associated with many demyelinating diseases. Recently, MOG-IgG-associated encephalomyelitis (MOG-EM) has been proposed as a disease entity with a preliminary diagnosis standard. Some patients with lung ...

    journal_title：Multiple sclerosis and related disorders

    pub_type：

    doi：10.1016/j.msard.2020.102064

    authors： Li K,Zhan Y,Shen X

    更新日期：2020-07-01 00:00:00

  • Clinical decision-making in multiple sclerosis: Challenges reported internationally with emerging treatment complexity.

    abstract：INTRODUCTION:The introduction of several new disease-modifying therapies (DMTs) to the field of Multiple Sclerosis (MS) treatment requires that MS healthcare providers have a comprehensive understanding of the implications of each new treatment option in order to select the treatment that best suits their patient. An i...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2015.05.008

    authors： Ng P,Murray S,Hayes SM

    更新日期：2015-07-01 00:00:00

  • Post herpes zoster infection neuromyelitis optica spectrum disorder.

    abstract：:Neuromyelitis optica is a severe autoimmune demyelinating disease; however, the trigger for autoimmunity in an individual patient is unclear. Here, we report the case of a 48 year old female presenting with longitudinally extensive transverse myelitis in the cervical region of the spinal cord two weeks post herpes zos...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2017.09.022

    authors： Mathew T,Thomas K,Shivde S,Venkatesh S,Rockey SM

    更新日期：2017-11-01 00:00:00

  • Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors.

    abstract：BACKGROUND:Increasing evidence for contribution of hemostasis components in multiple sclerosis (MS) has been reported. Hemostasis protein inhibitors display key regulatory roles, extending to regulation of innate immune response and inflammation, and promotion of blood-brain barrier integrity. Whereas the effects on he...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102319

    authors： Ziliotto N,Lamberti N,Manfredini F,Straudi S,Baroni M,Tisato V,Carantoni M,Secchiero P,Basaglia N,Marchetti G,Bernardi F

    更新日期：2020-09-01 00:00:00

  • Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.

    abstract：BACKGROUND:The presence of white mater lesions in the central nervous system forces the differential diagnosis between multiple sclerosis (MS) and Anderson-Fabry disease (FD). Due to the type of inheritance, linked to the X chromosome, the diagnosis of FD is especially difficult in women. Tissue´s deposits of globotria...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.101466

    authors： Olivera S,Iñiguez C,García-Fernández L,Sierra JL,Camón AM,Menao S,Torralba MÁ

    更新日期：2020-02-01 00:00:00

  • Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial.

    abstract：BACKGROUND:Cognitive impairment is common in multiple sclerosis (MS), but deficits tend to be more pronounced in progressive MS, negatively impacting daily functional capacity. Despite this, most cognitive rehabilitation (CR) interventions to date have focused on relapsing-remitting MS (RRMS). Moreover, information on ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.101932

    authors： Messinis L,Kosmidis MH,Nasios G,Konitsiotis S,Ntoskou A,Bakirtzis C,Grigoriadis N,Patrikelis P,Panagiotopoulos E,Gourzis P,Malefaki S,Papathanasopoulos P

    更新日期：2020-01-07 00:00:00

  • Neurosarcoidosis as an MS Mimic: The trials and tribulations of making a diagnosis.

    abstract：:The clinical presentation of neurosarcoidosis is varied as multiple levels of the neuraxis may be affected. When central nervous system involvement occurs, making an accurate diagnosis of the condition can be challenging, especially given the current definition for definite neurosarcoidosis requires histologic confirm...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2015.06.012

    authors： MacLean HJ,Abdoli M

    更新日期：2015-09-01 00:00:00

  • Does cognitive training improve attention/working memory in persons with MS? A pilot study using the Cogmed Working Memory Training program.

    abstract：BACKGROUND:Cognitive deficits, especially in attention, are common in persons with MS (PwMS) and are associated with clinically meaningful outcomes, such as work disability and lower quality of life (QOL). In this study, we aimed to determine whether Cogmed Working Memory Training (CWMT) improves attention/working memo...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2021.102770

    authors： Blair M,Goveas D,Safi A,Marshall C,Rosehart H,Orenczuk S,Morrow SA

    更新日期：2021-01-17 00:00:00

  • Improving MS patients' understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial.

    abstract：BACKGROUND:Multiple Sclerosis (MS) patients find it difficult to understand the complex risk-benefit profiles of disease-modifying drugs. An evidence-based protocol was designed to improve patient's understanding of treatment information: Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS). OBJE...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2021.102737

    authors： Reen GK,Silber E,Langdon DW

    更新日期：2021-01-12 00:00:00

  • The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

    abstract：OBJECTIVE:Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a duration of response exceeding the current licenced t...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章,评审

    doi：10.1016/j.msard.2020.102279

    authors： Baker D,Pryce G,James LK,Marta M,Schmierer K

    更新日期：2020-09-01 00:00:00

  • Weight status and disability in multiple sclerosis: An examination of bi-directional associations over a 24-month period.

    abstract：BACKGROUND:Natural history studies have typically focused on non-modifiable factors as predictors of disability progression in multiple sclerosis (MS). Weight status has emerged as a correlate of disability status in cross-sectional studies of persons with MS and represents a possible modifiable predictor of disability...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2012.02.004

    authors： Pilutti LA,McAuley E,Motl RW

    更新日期：2012-07-01 00:00:00

  • The epidemiology of multiple sclerosis in the Scottish Highlands: Prevalence, incidence and time to confirmed diagnosis and treatment initiation.

    abstract：INTRODUCTION:Although multiple sclerosis (MS) is frequent in the northern hemisphere, there have not been recent epidemiological studies in the Scottish Highlands about MS. OBJECTIVES:To get updated data regarding MS prevalence, incidence and mortality in the Highlands. Time between symptom onset and MS diagnosis was ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102657

    authors： Carod-Artal FJ

    更新日期：2020-11-28 00:00:00

  • Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis.

    abstract：BACKGROUND:The association between routine laboratory findings, including cerebrospinal fluid biomarkers, and neurological outcomes in patients with multiple sclerosis (MS) has not been fully elucidated. In this study, we evaluated blood and cerebrospinal fluid (CSF) analysis results at diagnosis and before treatment i...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102382

    authors： Akaishi T,Takahashi T,Fujihara K,Misu T,Nishiyama S,Takai Y,Fujimori J,Abe M,Ishii T,Aoki M,Nakashima I

    更新日期：2020-10-01 00:00:00

  • Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.

    abstract：OBJECTIVE:Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. BACKGROUND:Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The en...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2013.05.003

    authors： Thaera GM,Wingerchuk DM,Carter JL

    更新日期：2014-01-01 00:00:00

  • Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.

    abstract：:Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rat...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2015.04.005

    authors： Barroso B,Miquel M,Marasescu R,Demasles S,Krim E,Bonnan M

    更新日期：2015-07-01 00:00:00

  • Fatigue, depression, and physical activity in relapsing-remitting multiple sclerosis: Results from a prospective, 18-month study.

    abstract：BACKGROUND:Fatigue, depression, and physical inactivity are common in multiple sclerosis (MS), but there is limited information on the bi-directional associations among those variables over a long period of time. OBJECTIVE:This study examined the hypothesis that fatigue and depression would predict change in physical ...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2011.08.003

    authors： Motl RW,Suh Y,Weikert M,Dlugonski D,Balantrapu S,Sandroff B

    更新日期：2012-01-01 00:00:00

  • Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis.

    abstract：OBJECTIVE:Using spectral domain optical coherence tomography (SD-OCT), to compare the choroidal thickness in a healthy population (group 1), with newly diagnosed multiple sclerosis (MS) patients (group 2), with MS patients who underwent β-interferon monotherapy (group 3) and MS patients who underwent fingolimod therapy...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2017.03.005

    authors： Kal A,Oğuz Ulusoy M,Horasanlı B,Cezairlioğlu Ş,Kal Ö

    更新日期：2017-05-01 00:00:00

  • Cross-sectional survey of complementary and alternative medicine used in Oregon and Southwest Washington to treat multiple sclerosis: A 17-Year update.

    abstract：BACKGROUND:In 2001, we conducted a survey on use of complementary and alternative medicine (CAM) in people with multiple sclerosis (pwMS) in Oregon and Southwest Washington to treat their disease. OBJECTIVES, METHODS:In 2018, we administered a revised survey in the same region to describe updated patterns of CAM use i...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102041

    authors： Silbermann E,Senders A,Wooliscroft L,Rice J,Cameron M,Waslo C,Orban A,Chase E,Yadav V,Bourdette D,Spain RI

    更新日期：2020-06-01 00:00:00

  • Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.

    abstract：INTRODUCTION:Italy has been the first European country severely affected by the COVID-19 pandemic. OBJECTIVE:To analyze the incidence of the clinical presentations suggestive for COVID-19 infection among patients with Multiple Sclerosis in the province of Lecco, in the North Italy, the closest province capital to Berg...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102453

    authors： Mantero V,Abate L,Balgera R,Basilico P,Salmaggi A,Cordano C

    更新日期：2020-11-01 00:00:00

  • Peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography in different clinical subtypes of multiple sclerosis.

    abstract：BACKGROUND:Multiple sclerosis (MS) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system (CNS) with axonal degeneration as major determinant of neurological disability. Assessment of unmyelinated retinal nerve fibers using optical coherence tomography (OCT) may be useful for diagnosin...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2018.11.003

    authors： Jankowska-Lech I,Wasyluk J,Palasik W,Terelak-Borys B,Grabska-Liberek I

    更新日期：2019-01-01 00:00:00

  • Multimodal neurophysiological evaluation of primary progressive multiple sclerosis - An increasingly valid biomarker, with limits.

    abstract：BACKGROUND:The promising utility of multi-modality evoked potential batteries to objectively measure multi-tract dysfunction has been evaluated by several groups using different methods. OBJECTIVE:To independently evaluate the use of multi-modality evoked potential batteries as surrogate biomarkers for both physical a...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2015.07.009

    authors： Canham LJ,Kane N,Oware A,Walsh P,Blake K,Inglis K,Homewood J,Witherick J,Faulkner H,White P,Lewis A,Furse-Roberts C,Cottrell DA

    更新日期：2015-11-01 00:00:00

  • Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.

    abstract：BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is a complex disease characterized by a severe inflammation of the central nervous system (CNS). This disease typically manifests with recurrent optic neuritis (ON) and acute transverse myelitis (ATM). The clinical and radiological spectrum of NMOSD is little kn...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2020.102208

    authors： Edgar Patricio CD,Eleanor THG,Francisco José CZ,Gabriela ACM,Hyland AO,Fernando GL,María TA,Beatriz N,Marcos SD,Alfredo GPW

    更新日期：2020-09-01 00:00:00

  • A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.

    abstract：:Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting multiple sclerosis (MS). It should be stopped at least two months before conception as it is not considered safe during pregnancy or when breast feeding. In vitro and animal studies have found a possibly increased risk of conge...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2018.02.015

    authors： Navardi S,Sahraian MA

    更新日期：2018-04-01 00:00:00

  • Erythroblast appearance associated with natalizumab.

    abstract：:Despite having a high rate of occurrence, erythroblast appearance in peripheral blood may not be a recognized adverse effect of natalizumab (NTZ) treatment. Additionally, the time course and cause of erythroblast appearance remain unclear. We report two cases of multiple sclerosis wherein NTZ treatment led to erythrob...

    journal_title：Multiple sclerosis and related disorders

    pub_type： 杂志文章

    doi：10.1016/j.msard.2019.01.041

    authors： Kobayashi Y,Takamatsu R,Sato S,Watanabe R,Hoshi K,Ishii W,Yahikozawa H

    更新日期：2019-04-01 00:00:00